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Abstract
Purpose To describe and assess the outcomes of Peri-
odic Safety Update Report (PSUR) evaluations of
biopharmaceuticals.
Methods A cross-sectional analysis was performed of
follow-up requirements of PSURs submitted for central-
ly approved biopharmaceuticals in the European Union
between 1 July 2008 and 30 June 2010. A follow-up
analysis on a subset of products that submitted multiple
PSURs within the study period was also performed.
Results The cross-sectional analysis included 70 PSURs.
Potential safety concerns occurred in 57 (83 %) of all
PSURs, and 26 (37 %) concluded a need to change the
Summary of Product Characteristics (SPC). In compari-
son to newer products, products authorized for more
than 10 years contained significantly fewer potential
safety concerns (60 vs. 92 %; p<0.01) and required
fewer SPC changes (15 vs. 46 %; p00.03). For 45
products, multiple PSURs were submitted that could
be included in a follow-up analysis. For this subset of
products, of the 106 newly identified safety potential
safety issues, 7 (7%) resulted in requirements for label
changes in the following PSUR.
Conclusions PSURs facilitate communication between
regulators and marketing authorization holders. Poten-
tial safety concerns occur for the majority of biophar-
maceuticals and throughout their lifecycle, but for
established products PSUR evaluations rarely lead to
regulatory actions.
Keywords Periodic Safety Update Report .
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Introduction
Marketing authorization holders (MAHs) have the ob-
ligation to monitor the safety of their products after
their product receives marketing authorization. As such,
they are engaged in continuous dialogue with regula-
tors to ensure that the right strategies are employed to
optimize the benefit to risk ratio of their products. One
of the main tools used to facilitate post-authorization
communication between MAHs and regulators is the
Periodic Safety Update Report (PSUR). PSURs aim to
provide an update of worldwide safety experience with
a specific pharmaceutical. It includes data from spon-
taneous reports, safety data from interventional and/or
observational studies, as well as other relevant safety
information (Table 1) [1]. PSURs are intended to pro-
actively present, analyze, and evaluate new or changing
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safety data from any source evaluated in relation to
estimates of exposure to the product, although total
coverage of data sources may have limitations in prac-
tice [2]. PSURs are composed by MAHs and submitted
to regulatory authorities for assessment at predeter-
mined time points [1]. In the European Union (EU),
PSURs also need to be submitted alongside applica-
tions to renew the initial marketing authorization,
which is valid for a period of 5 years. Both regulatory
authorities and MAHs spend significant resources on
the creation and assessment of PSURs [3]. However,
the outcomes of these efforts have not been well
described.
The concept of PSUR reporting in its current form
stems from 1992 [4]. It has been noted at several ‘plat-
forms’, including the International Conference of Har-
monization (ICH) and the EU, that PSUR reporting has
not kept pace with developments in pharmacovigilance,
such as electronic adverse event reporting and risk
management planning [5–7]. In 2010, this awareness
resulted in changes in European legislation laying
down the requirements for PSUR reporting [8]. In an
earlier study on the determinants of safety-related reg-
ulatory actions for biopharmaceuticals, we found that
PSUR evaluations contributed to 38 % of post-
authorization regulatory actions in a sample of biophar-
maceuticals [9]. In addition, in 2010, Alvarez et al.
found that 64 % of a selection of adverse drug reac-
tions (ADRs) originated from PSURs [10]. Both these
studies examined the contribution of PSURs to identi-
fied safety signals, which does not provide insights as
to how PSURs contribute to monitoring safety, or
which fraction of PSURs leads to regulatory action.
Multiple factors, including product characteristics, reg-
ulatory approval status and timing of approval could
potentially affect the outcome of PSUR evaluations.
Therefore, this study aims to address two topics: (1)
to evaluate the outcomes of PSUR evaluations and
identify determinants for PSURs that lead to regulatory
actions, defined as safety-related changes, to the prod-
uct labeling; (2) to assess the outcomes of safety-
related follow-up requirements that resulted from PSUR
Table 1 Structure and content of a Periodic Safety Update Report
Structural components of a PSUR Description
Title page
Executive Summary
Introduction Includes information on the product(s) included in the PSUR and placed into
perspective of previous PSURs
Worldwide market authorization status An overview of all the countries where the product is authorized, including differences
in qualifications or indications
Update of regulatory authority or MAH actions
taken for safety reasons
Worldwide Actions relating to safety that were taken during the period covered by the
PSUR (or between data lock point and PSUR submission).
Changes to reference product information Changes such as contraindications, precautions, warnings, adverse reactions, or
interactions already made during the PSUR period should be described.
Patient exposure An estimate of the patient exposure during the PSUR period and the method used
to derive this estimate
Presentation of individual case histories A description and analysis of selected cases, including fatalities, presenting new and
relevant safety information. Includes a discussion of spontaneous reports, literature
reports, reports originating from PASS or consumer reports
Studies Discussion of data from studies that could potentially impact the product information.
This includes newly analyzed company sponsored studies, targeted safety studies
examining specific safety concerns and published studies.
Other information Discussion on efficacy-related information, late breaking information and a discussion
of the risk management plan
Overall safety evaluation A concise discussion on all the data presented highlighting changes in both listed and
unlisted adverse events
Conclusion Assessed of all data in relation to the reference safety information and recommended
action to be taken
Appendices Including the Company Core Data Sheet, detailed information on ADRs in line listings
and summary tabulations.
PSUR, Periodic Safety Update Report; MAH, marketing authorization holder; ADRs, adverse drug reactions
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assessment. Several recent studies have reported on the
specifics of pharmacovigilance for biopharmaceuticals.
The nature of reported adverse events for biopharma-
ceuticals seems to differ from those for small mole-
cules, which may lead to different safety-related
regulatory actions and could necessitate a distinctive
pharmacovigilance approach [11, 12]. To add to this
work and to increase the understanding of the perfor-
mance of pharmacovigilance activities in the safety




A cross-sectional analysis was performed of all PSURs
and PSUR assessment reports (PARs) created for bio-
pharmaceuticals centrally approved in the EU since
1995. Biopharmaceuticals are defined as therapeutic pro-
teins with active agents inherently biological in nature
and manufactured using biotechnology, including recom-
binant therapeutic proteins (including antibodies),
nucleic-acid based products and engineered cell or
tissue-based products [13]. For the purpose of our study
we excluded vaccines, diagnostics and extracted prod-
ucts that are not manufactured using biotechnology (e.g.
proteins and/or blood products extracted from non-
engineered sources).
PSURs and PARs were obtained from the repository
of the Dutch Medicines Evaluation Board (CBG-MEB).
As PSURs contain proprietary information, the data
were confidentially collected and analyzed in an aggre-
gated fashion. For the main analysis, each first PSUR
submitted for each product in a recent timeframe (1 July
2008 to 30 June 2010) was included (Fig. 1). Because
of the intrinsic limitations of the electronic repository,
only these more recent PSURs could be included, which
limited the long-term follow-up of individual products.
Authorization details of the products were obtained from
European Public Assessment Reports (EPARs), which
are available from the website of the European Medi-
cines Agency (EMA) [14]. The position of the biophar-
maceutical in the Anatomic Therapeutic Classification
(ATC) was determined using the website of the World
Health Organization (WHO) Collaborating Center for
Drug Statistics Methodology [15]. Authorization times
were based on the international birth date, which is the
first date of marketing authorization anywhere in the
world. All other product-related information was
obtained from the PSURs and PARs.
Scoring procedure
PSURs and PARs were analyzed for follow-up ‘require-
ments’, which included both commitments proposed by
the MAH and requirements from the assessor at the regula-
tory authority. If these conflicted, the requirement within the
PAR was included in the analysis. We created a scoring
method analogous to the safety specification of Risk Man-
agement Plans in which we categorized follow-up require-
ments as ‘identified risks’, ‘potential risks’ and ‘presentation
of risk data’ [1] (Box 1). In addition, categories for quality-
related issues and other, non-safety-related follow-up
requirements were created.
When a single safety concern included multiple follow-
up requirements to address the potential risks (category 2),
each was scored once according to the following ‘hierar-
chy’: cumulative reviews > close monitoring of a potential
new safety concern > continued close monitoring of a po-


















Fig. 1 Graphical representation
of the possible Periodic Safety
Update Reports (PSURs)
included in the study. X PSURs
included in the main analysis,
Xδ PSURs included in the
follow–up analysis. Each third
or more PSUR submitted within
the study period was excluded,
as indicated by the dashed Xn
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safety concern. For example, if for a given product that was
being closely monitored a cumulative review was required,
this was scored only once as a cumulative review. All
frequencies were recorded and recoded into dichotomous
(Y/N) variables for the main analysis. The dataset was
scored by a single rater (HE). To test the reliability of the
scoring procedure, 14 randomly selected products, including
214 items, were scored by two independent assessors (HE
and MP), disagreement was resolved by consensus. Agree-
ment between initial scoring and consensus was good (κ 0
0.93) on individual items. In 5 of 14 products this led to an
altered overall score in one or more of the 11 dichotomous
variables. The results of which were include in the final
dataset.
Follow-up analysis of the outcome of new potential safety
concerns
For the subset of products for which two or more
PSURs were submitted within the study period, we
performed an analysis of follow-up requirements (Fig. 1).
We assessed the second of two consecutive PSURs for
co-occurrence of events that were scored as new poten-
tial safety issues in the first PSUR. New potential safety
issues were defined as all safety concerns in the first
PSUR which resulted in requirements for either a ‘cu-
mulative review’ or ‘close monitoring of potential new
safety concern’.
Data analysis
All data were entered into a database and analyzed using
SPSS Statistics software package, ver. 19.0.0 (SPSS,
Chicago, IL). Associations between requirements for
Summary of Product Characteristics (SPC) changes and
determinants, including product characteristics, regulatory
authorization characteristics and time since approval, were
tested using two-sided Fisher’s exact tests at an α level
of 0.05. Ratios were calculated using Epi InfoTM v.
7.0.8.0 [Centers for Disease Control and Prevention
(CDC), Atlanta, GA].
Box 1 Scoring procedure of follow-up requirements. Safety concerns were scored once in each category
Structural components of a PSUR Description
1. Identified Risks a. Requirements to change to the current Summary of Product Characteristics (SPC).
2. Potential risks (Safety-related follow-up
requirements)
a. Provision of a review of all data on a possible safety concern, either in the next
PSUR or before the next PSUR (‘cumulative review’).
b. Requirements to closely monitor cases of new (suspected) safety concerns in
forthcoming PSURs. Such concerns are discussed in detail in each PSUR.
c. The continued close monitoring of safety concerns that had been previously identified,
this included all items that were described as ‘under heightened surveillance’.
d. Instances when it was explicitly mentioned that a previous requirement for
continuous monitoring was no longer required, this includes statements that a
previously identified safety concern is now subject to ‘routine monitoring’.
e. Requirements to provide additional information on a possible safety concern that did
not require a cumulative review of data or the continued monitoring were included in
this category. This includes requirements to comment on individual cases, studies
included in the PSUR or on the results of a previously presented cumulative review.
3. Presentation of risk data a. Requirements to provide information that was missing in the current PSUR, e.g.
missing analyses not related to a specific safety concern. For example, results of a
safety study that were not discussed, or missing estimates of patient exposure.
b. Requirements to present the information in another way to facilitate the assessment of
the PSUR. Examples of this category were requirements to split data for different
approved indications or presenting data for patient sub groups.
4. Quality related follow-up requirements. a. Clarification of discrepancies within the PSUR (e.g. between tables and texts, or
between tables and case reports).
b. Requirements for improving the quality and/or follow-up of individual case reports
were included in this category.
5. All other follow-up requirements a. This included requirements unrelated to the safe use of the product, comments on the
provision of study reports, remarks that did not require follow-up, updates of ongoing
regulatory procedures, changes in SPC wording of safety issues that were identified
before the current PSUR assessment pro
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Results
Summary characteristics
We identified 115 biopharmaceutical products that were
approved during the study period. Of these, 33 did not
submit PSURs during the study period, and 12 were exclud-
ed because multiple products were included in a single
PSUR (all fast- and intermediate-acting insulins and biosi-
milars sold under different trade names). Therefore, the final
analysis included 70 PSURs (Table 2). The median time
between authorization and the date of submission of the first
included PSUR was 6.9 (range 0.6–24.6) years. Monoclonal
antibodies and hormones accounted for over half of the
products in the sample. Most products belonged to the
ATC groups of antineoplastic and immunomodulating
agents (n026), blood and blood-forming organs (n016)
and alimentary tract and metabolism (n013).
The characteristics of PSURs varied considerably for the
different products. The median length of PSURs was 396
(range 15–30,901) pages. Excluding the appendices that
contained detailed information on individual cases in so-
called ‘line listings’, the median length of a PSUR was 69
(range 9–949) pages. The median length of a PAR was 17
(range 2–82) pages. Each PSUR contained a median of 305
case reports; some reports included over 12,000 case
reports, describing over 20,000 adverse events.
Cross-sectional analysis of PSUR assessments
Identified safety concerns, such as changes to the SPC, were
included in 27 (39 %) of the PSURs. In one case, this
required communication to healthcare professionals through
a so-called Direct Healthcare Professional Communication.
Potential safety concerns were present in 58 (83 %) of the
PSURs (Fig. 2). New potential safety concerns were identi-
fied in 23 (33 %) of the PSURs, and 55 (79 %) of all the
assessments resulted in the continued monitoring of a pre-
viously identified safety concern. The number of concerns
that were closely monitored ranged from one to 34 concerns
per PSUR. For 46 (66 %) of the products, either changes to
the presentation of risk data were required or quality issues
were identified. Five (7 %) of the PSURs did not result in
any follow-up requirement. Excluding PSURs that were
submitted for products that were suspended at the time of
submission (n02), none of the PARs concluded that the
overall benefit/risk (B/R) balance had change—for all
assessed products the benefits continued to outweigh the
risks.
The proportion of PSUR assessments that led to pro-
posals for SPC changes in relation to various subgroups
is shown in Table 3. Requirements for SPC changes
occurred most frequently for a PSUR submitted within
5–10 years of authorization and significantly less fre-
quently for products older than 10 years (p<0.05). With
the exception of recombinant blood products, SPC
changes were required for products belonging to all
mechanistic classes. The proportions of PSURs that
resulted in safety-related follow-up requirements were
highest for the classes of interferons and monoclonal
antibodies and lowest for recombinant blood factors, hor-
mones and growth factors. Changes to the SPC were
required most often for products of the ATC class of
antineoplastics and immunomodulators when compared
to all other ATC classes (p00.01). No significant differ-
ences were found for other ATC classes. Safety-related
follow-up requirements occurred throughout the lifecycle
of the products. However, the proportion of PSURs that
included follow-up requirements to address potential risks
was significantly lower for products that were older than
10 years (65 vs. 90 %; p<0.01).
Contribution of follow-up requirements in identifying new
safety concerns
For 45 products, multiple PSURs were submitted during the
study period. In 28 (62 %) of these, potential new safety
concerns were identified, amounting to 106 new potential
safety-related follow-up requirements. This included 69
requirements for ‘cumulative reviews’ of data on potential
safety concerns and 37 requirements for the initiation of
‘monitoring potential new safety concerns’ (Fig. 3). Of these
106 new potential safety concerns, seven (7 %) resulted in
SPC changes in the following PSUR, 55 (53 %) resulted in
an additional safety-related follow-up requirement and 31
(29 %) required no follow-up. For the remaining 11 (10 %)
of the issues addressed, no reference could be identified.
Discussion
We evaluated the role of PSURs in facilitating authorization
communication between regulators and MAHs. Our results
show that 37 % of the PSUR assessments of the biopharma-
ceuticals included in our study concluded that a change in
the product labeling was needed. Potential safety concerns
continued to emerge throughout the lifecycle of these bio-
pharmaceuticals, and safety-related follow-up measures
were required for 83 % of all these products. Despite the
fact that new potential safety concerns were identified in the
majority of PSURs, a minority (9 %) of these requirements
led to regulatory action in the following PSUR.
How does PSUR assessment contribute to finding new
safety concerns? PSURs were cited as a contributing source
in 40 % of the type II variations in a study of a sample of
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biopharmaceuticals [9]. Alvarez et al. found that in 64 % of
a selection of safety signals, the earliest detection could be
traced back to PSURs. The results of our study seem to
confirm that PSURs contribute to a significant portion of the
post-approval product label changes. However, the majority
of the follow-up requirements that addressed these new
potential safety concerns did not result in regulatory action,
but most resulted in additional follow-up requirement. Of all
the safety-related follow-up requirements, 7% resulted in
SPC changes indicating a modest additional impact of
follow-up requirements to monitor or review specific safety
concerns. None of the PSURs included in our analysis
identified a shift in the overall B/R balance of the product.
It has been noted that PSURs are not intended to be a ‘signal
detection tool,’ but rather as a tool to periodically re-
evaluate the overall safety profile of a medicinal product
[16]. This periodicity ensures a weighing of all the available
evidence, but may preclude PSURs from contributing to
urgent regulatory actions. On the other hand, if the PSUR
assessment process never results in some form of regulatory
action, one can question whether PSURs are the most effec-
tive regulatory instrument to manage the post-approval safe-
ty of medicines.
We did not differentiate between proposals by the MAHs
and requirements originating from the assessor at the regu-
latory agency. However, we did identify a considerable
number of PSURs (46; 66 %) with quality issues or with
requirements to provide missing data. Thus, the assessment
procedure ensures that the task of evaluating the data will be
performed meticulously and thoroughly. We did not evalu-
ate if such quality-related follow-up requirements contribute
to the initiation of regulatory actions.
Despite the introduction of a harmonized format in 1996,
PSURs differ considerably in structure, content and presenta-
tion of safety data, which may complicate the assessment
procedure. These differences may originate from the fact that
different companies have different working methods, but also
because regulators require data to be presented or analyzed in
Table 2 Key characteristics of




aFor several biosimilar products
‘Joint PSURs’ were created that
contained safety information of
the same molecule marketed un-
der various names. 1: Abseamed,
binocrit and epoetin hexal; 2: fil-
grastim hexal and Zarzio; 3: teva-
grastim, biograstim, ratiograstim
and filgrastim ratiopharm
Key characteristics n %
Total 70 100
Regulatory approval characteristics
Approved under exceptional circumstances 2 2.9
Orphan status 3 4.3
Both exceptional circumstances and orphan status 5 7.1
Regular approval 60 85.7






Growth factors 8 11.4
Hormones 18 25.7
Interferons 6 8.6
Monoclonal antibodies 19 27.1




A: Alimentary tract and metabolism 13 18.6
B: Blood and blood forming organs 16 22.9
H: Systemic hormonal preparations, excl. sex hormones and insulins 6 8.6
L: Antineoplastic and immunomodulating agents 26 37.1
M: Musculo-skeletal system 4 5.7
R: Respiratory system 1 1.4
S: Sensory organs 1 1.4
V: Various 3 4.3
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different ways. European legislation has been adopted that
stipulates changes to pharmacovigilance requirements, includ-
ing PSUR reporting. For example, detailed information of
adverse drug reactions is only to be submitted to the European
adverse event database (EudraVigilance). In addition, for ge-
neric products and products with well-established therapeutic
use, PSURs will no longer be routinely required [8]. Although
intended to be summaries of adverse events to facilitate a
periodic safety evaluation, many PSURs are long and com-
plicated documents. The new format requires a more concise
document that includes a discussion of both the benefits and
risks, with an emphasis on identifying changes in the overall
B/R balance. Similar proposals have also been released for
consultation by the ICH [6]. In addition to the increased
emphasis on B/R assessments, the ICH proposes a modular
design to facilitate differences in international reporting
requirements and a greater harmonization with pre-
authorization safety reports. Routine monitoring of the out-
come of PSUR assessments may provide valuable information
for the evaluation of the impact of these regulatory changes.
In our analysis, the follow-up requirements differed con-
siderably in terms of their level of detail. For example,
some safety concerns, described requirements to monitor
the broad category of ‘infections’ or ‘malignancies’, while
others required the follow-up of the more specific safety
concerns ‘progressive multifocal leukoencephalopthy’ or
‘tuberculosis’. This difference posed a challenge in compar-
ing the outcomes of different assessment reports. Therefore,
it was decided to use dichotomous (Y/N) variables regard-
less of the level of detail included. In addition, many assess-
ments lacked uniform structure and terminology. Although
this is an inevitable result of differences between individual
assessors, it also indicates a lack of European standards and
protocols for assessing PSURs. Increased harmonization of
the assessment procedure may improve the overall process.
The use of harmonized terminology for adverse events using
the Medical Dictionary for Regulatory Activities (MedDRA)
has facilitated the identification and communication of safety
issues [17]. The establishment of accepted terminology for
follow-up requirements could further harmonize the PSUR
assessment process, whichmay contribute to the quality of the
procedure.
We chose SPC variations as an outcome measure for
regulatory action because the SPC is the main risk com-
munication method employed by European regulators and
because they could be most reliably identified [18]. This
should not be interpreted as if the effectiveness of post-
approval safety is reflected only in the proportion of SPC
variations—i.e. the absence of a safety concern in the
study period does not necessarily signify that regulatory
oversight is falling short. Finally, it has been questioned
whether product labeling is an effective risk minimization
instrument [19, 20]. This question was beyond the scope
of the current study.
We found that regulatory actions occurred significantly
more often after assessment of PSURs of products belong-
ing to the ATC class of ‘immunomodulators and antineo-
plastic agents.’ This class contained more products with a
unique target (mostly monoclonal antibodies) relative to the
class of hormones, for example, which included several
products with the same target for which extensive experi-
ence had been gained, such as insulins and erythropoietins
and several biosimilars. Nevertheless, there may be products
that hold a greater risk of post-approval safety concerns,
warranting a risk-based approach toward PSUR reporting
requirements. This conclusion is in line with the results of a
study which reported that a large proportion of post-
approval safety warnings issued for biopharmaceuticals are
related to their immunomodulatory effects [12].
It has been previously demonstrated that about one-third of
post authrorization safety communications concern products
which have been authorized for more than 10 years [21]. Our
data suggest that PSUR assessments, at least for biopharma-
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Fig. 2 Outcome of PSUR assessments. Percentage of PSUR evaluations that included at least one of the outcomes
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throughout their lifecycles. Given the fact that the safety
profile of newly authorized products is not well established,
a carefully designed pharmacovigilance program is
particularly important at the early stages of drug authorization
[22]. However, for products approved for longer than 10 years,
the frequency of SPC changes was significantly lower com-
Fig. 3 Outcome of new
potential safety concerns.
Potential safety concerns
identified in the first of two
consecutive PSURs were
defined as either requests for
cumulative reviews or the
monitoring of potential new
safety concerns. The vertical
axis shows the outcome of
the potential safety concern
in the following PSUR. SPC
Summary of Product
Characteristics




*p<0.05 (2-sided Fisher’s exact
test)
SPC, Summary of Product
Characteristics








Period covered by PSUR
≤6 months (n026) 8 (31 %) 1 (reference)
>6 months - 12 months (n024) 11 (46 %) 1.49 0.72 3.07
>12 months (n020) 7 (35 %) 1.14 0.50 2.61
Period between international birth date and date of PSUR
>10 years (n020) 3 (15 %) 1 (reference)
5–10 years (n026) 14 (54 %) 3.59* 1.19 10.81
0–5 years (n024) 9 (38 %) 2.50 0.78 8.01
Mechanistic class
All other products (n033) 10 (30 %) 1 (reference)
Monoclonal antibodies (n019) 11 (58 %) 1.91 1.00 3.64
Hormones (n018) 5 (28 %) 0.92 0.37 2.27
ATC class
All other products (n044) 11 (25 %) 1 (reference)
Immunomodulators & antineoplastics
(n026)
15 (58 %) 2.31* 1.26 4.24
First in ATC class
Yes (n011) 3 (27 %) 1 (reference)
No (n059) 23 (39 %) 1.43 0.52 3.95
Biosimilar
Yes (n06)a 2 (33 %) 1 (reference)
No (n064) 24 (38 %) 1.08 0.33 3.50
Orphan drugs
Yes (n08) 2 (25 %) 1 (reference)
No (n062) 25 (40 %) 1.61 0.47 5.56
Approved under exceptional circumstances
Yes (n07) 1 (14 %) 1 (reference)
No (n063) 25 (40 %) 2.78 0.44 17.49
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pared to younger products, supporting reduced PSUR report-
ing requirements for established products, as proposed by the
new European pharmacovigilance legislation. However, our
study included 70 PSURs, which limited the ability to dem-
onstrate statistically significant differences between the fre-
quencies of required SPC changes within subgroups.
The PSUR evaluations which we assessed rarely con-
cluded that a safety signal was no longer considered a
safety concern. This may eventually lead to great volumes
of information that need to be reviewed even in the
absence of real safety problems [23]. It is recognized that
the ‘demonstration’ of the absence of a safety risk is very
challenging. In practice, the assessment procedure is more
focused on identifying new potential risks, rather than
concluding that there is no evidence to support a previous
safety concern.
Our study focused on the assessment of PSURs in
Europe. Other regions have been reported to operate differ-
ently with regard to the handling and assessment of adverse
event information, including PSURs [24]. An analysis of the
PSUR assessment procedure in other regions could thus
yield different results.
Unlike for biopharmaceuticals, adverse events of small
molecules are often related to toxicity and/or overdose.
Data on this is usually lacking at the time of authorization
and is added to the label through post authorization SPC
updates [25]. In addition, unlike the case for biopharmaceut-
icals, safety events of small molecules are included in a
considerable number of post-approval regulatory actions
related to toxicity as a result of overdose, data which are
often lacking at the time of authorization and which may be
included in post-authorization SPC updates [26]. Therefore,
it could be that for small molecules the outcome of pharma-
covigilance activities differ, and future research could com-
pare our results with those for small molecules.
A major problem when assessing the contribution of
PSURs in the safety management of (bio)pharmaceuticals
is the lack of a control group. As PSURs are mandatory for
all products, it is not possible to determine whether safety
findings would also have been identified and managed with-
out them. Furthermore, PSURs are not publicly available,
which complicates the assessment of their role in relation to
other post-approval activities. Wider access to PSUR data
would facilitate future studies into the role of PSUR report-
ing. In addition, PSURs also serve as a vehicle to monitor
and streamline regulatory procedures, such as risk manage-
ment plans and marketing authorization renewal procedures.
We examined the role of PSURs, but their value should be
considered in conjunction with all available regulatory
instruments.
In conclusion, oversight is clearly needed to ensure that a
product’s benefits continue to outweigh its risks, and PSURs
facilitate the weighing and monitoring of such events at
predetermined time points. As such, PSURs are clearly a
vehicle to drive regulatory dialogue, but determination of
their contribution to the safe use of medicines as ancillary to
existing pharmacovigilance requirements remains a
challenge.
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